<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-1OO81IVV/9d5b3f77-689f-4de9-9841-cff715c26125/PDF"><dcterms:extent>597 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-1OO81IVV/224ed097-6ef7-4507-b15e-fb0943644900/TEXT"><dcterms:extent>22 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-1OO81IVV"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2025</dcterms:issued><dc:creator>Ihan, Alojz</dc:creator><dc:creator>Oražem, Miha</dc:creator><dc:creator>Velenik, Vaneja</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:59</dc:format><dc:format xml:lang="sl">str. 252-256</dc:format><dc:identifier>DOI:10.2478/raon-2025-0034</dc:identifier><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID_HOST:241131267</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-1OO81IVV</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Croatian Medical Association - Croatian Society of Radiology</dc:publisher><dc:publisher xml:lang="sl">Slovenian Medical Society - Section of Radiology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">kompletno neoadjuvantno zdravljenje</dc:subject><dc:subject xml:lang="sl">radiation-induced lymphopenia</dc:subject><dc:subject xml:lang="sl">rak danke</dc:subject><dc:subject xml:lang="sl">rectal cancer</dc:subject><dc:subject xml:lang="sl">total neoadjuvant treatment</dc:subject><dc:subject xml:lang="sl">z obsevanjem povzročena limfopenija</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Sequencing of chemotherapy in total neoadjuvant treatment for rectal cancer does not predict radiation-induced lymphopenia|</dc:title><dc:description xml:lang="sl">Radiation-induced lymphopenia (RIL) is associated with an increased risk of death in solid tumors, including rectal cancer. The aim of this study was to determine whether the sequencing of chemotherapy in total neoadjuvant treatment (TNT) for rectal cancer predicts the development of RIL. Patients and methods We analyzed acute hematologic toxicity data from 53 patients who underwent TNT for locally or locoregionally advanced rectal cancer between July 2022 and April 2023. Twenty-eight patients received induction chemotherapy with capecitabine and oxaliplatin CAPOX, and 25 received consolidation chemotherapy (6 cycles of CAPOX in both groups). The chemoradiation protocol consisted of Volumetric Modulated Arc Therapy with Simultaneous Integrated Boost Radiotherapy (VMAT-SIB RT) up to 48.4 Gy in 22 fractions, concomitantly with capecitabine twice a day (lat. bis in die, BID). The Mann-Whitney U test was performed to compare RIL between the two patient groups. Pelvic bone marrow was contoured as a non-limiting organ-at-risk to assess the received dose, and binary logistic regression was used to determine whether RIL depends on V5Gy~V42Gy or the planning target volume (PTV) size. Results Thirty-four patients (64.2%) developed RIL of any grade, which was not significantly associated with either the induction or consolidation chemotherapy TNT regimen (Wald = 3.159, p = 0.076). No significant differences were found in neutrophil counts or the neutrophil-to-lymphocyte ratio. In the logistic regression model predicting the likelihood of RIL, two variables were statistically significant: V10Gy (Wald = 4.366, p = 0.037) and V30Gy (Wald = 6.084, p = 0.014). These results indicate that V10Gy&lt; 71% and V30Gy&lt; 26.6% may reduce the likelihood of developing RIL. Conclusions In our study, the sequencing of chemotherapy in TNT for rectal cancer did not predict the development of RIL. However, the incidence of RIL may be reduced by applying RT dosimetric constraints to the pelvic bone marrow</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-1OO81IVV"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-1OO81IVV" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-1OO81IVV/9d5b3f77-689f-4de9-9841-cff715c26125/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-1OO81IVV/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-1OO81IVV" /></ore:Aggregation></rdf:RDF>